KR20170055701A

KR20170055701A - Composition for prevention or treatment of neurodegenerative diseases

Info

Publication number: KR20170055701A
Application number: KR1020150158764A
Authority: KR
Inventors: 최병태; 백진웅; 신화경
Original assignee: 부산대학교 산학협력단
Priority date: 2015-11-12
Filing date: 2015-11-12
Publication date: 2017-05-22
Also published as: KR101793503B1

Abstract

The present invention relates to a composition for preventing, ameliorating or treating degenerative brain diseases, and more particularly, to a composition for preventing, ameliorating or treating degenerative brain diseases. More particularly, the present invention relates to a composition for inhibiting caspase- Improvement or treatment of degenerative brain diseases, which have a protective effect on nerve cells by inhibiting the death and increasing the activity of pCREB in neurons.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for preventing,

The present invention relates to a composition for preventing, ameliorating or treating degenerative brain diseases, and more particularly, to a composition for preventing, ameliorating or treating degenerative brain diseases comprising a complex extract of ginseng, omija, and rhubarb as an active ingredient.

In modern life, memory is becoming increasingly important in rapidly changing lives, and it has become a major interest from young people with a lot of social skills to old age. The deterioration of these functions is a social problem, and the deterioration of memory in the possibility of social life is a very important factor for patients who are relaxed to degenerative diseases such as dementia in the society where the proportion of the elderly population is increasing. Dementia is a disease that makes people and the people around them worse off individually and socially, and is the fourth cause of cancer deaths, heart disease and stroke. Dementia is divided into Alzheimer's dementia and vascular dementia. Alzheimer's dementia is a type of dementia observed in western countries. It is a disease in which cholinergic neurons are destroyed by accumulation of beta-amyloid in specific parts of the brain. Vascular dementia is a dementia caused by hypertension, stroke, hyperlipidemia, etc., resulting in ischemic conditions due to abnormal blood vessels to the brain, resulting in death in the hippocampus and peripheral nervous system. These two forms of dementia have different mechanisms but have the same mechanism in that they result in decreased memory capacity by decreasing the action of acetylcholine, which is known as memory neurotransmitter.

Efforts have been made to develop various therapeutic strategies to improve and improve the cognitive function and learning function deteriorated due to recent dementia and to develop effective drugs. The memory-improving drugs developed so far include acetylcholine precursors, receptor agonists, and acetylcholine esterase inhibitors. However, there have not been developed therapeutic agents capable of treating the underlying cause of Alzheimer's disease so far. Common therapeutic agents include Aricept, an acetylcholinesterase inhibitor of Pfizer, Exelon of Novartis, Reminyl, and recently Ebixa (Memantine) from Lundbeck, an antagonist of NMDA receptors licensed from the US FDA. However, acetylcholinesterase inhibitors improve the declining cognitive ability and do not cure the underlying cause of Alzheimer's disease. In addition, some patients only temporarily alleviate symptoms, but the effect is not long-lasting, so it is hard to say the fundamental treatment. In addition, due to the nature of the disease, a long-term use is required. In the case of the above-mentioned medicines, accompanying with various side effects such as hepatotoxicity, vomiting, loss of appetite and the like also appear to be problems. Therefore, it is urgent to develop a therapeutic agent that can prevent the progress of the disease. To this end, many multinational pharmaceutical companies are investing heavily in research and development in this field. In particular, beta or gamma secretease, which reduces the amount of beta amyloid composed of about 40 amino acids, which is presumed to be a fundamental cause of Alzheimer's disease The development of inhibitors is the dominant species. In Korea, basic research on Alzheimer's disease has been done to some extent, but the development of dementia treatment itself is rarely done.

Korean Patent Publication No. 10-2003-0021532

In order to solve the above problems of the prior art, the present invention provides a method for inhibiting neuronal cell death by inhibiting caspase-3 expression of hippocampus, It is intended to provide a composition for preventing, ameliorating or treating diseases.

It is another object of the present invention to provide a composition which is effective for preventing, improving or treating degenerative brain diseases caused by the death of nerve cells.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing or treating degenerative brain diseases comprising an extract of Ginseng, Omija, and Rhizoma as an active ingredient.

It is preferable that the ginseng, the omija, and the ginseng are mixed at a weight ratio of 0.1 to 10: 0.1 to 10: 0.1 to 10.

It is preferable that the combined extract of ginseng, omija, and guinea pig is contained in an amount of 0.001 to 99.9% by weight based on the total weight of the composition.

The present invention also provides a food composition for preventing or improving a degenerative brain disease, which comprises a combined extract of ginseng, omija, and rhubarb as an active ingredient.

According to the present invention, neuronal cell death is inhibited by the inhibition of caspase-3 expression of hippocampus, and neuronal cells are protected by an increase in pCREB activity in neurons, thereby preventing degenerative brain diseases Prevention, amelioration or treatment of stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, ischemic brain disease, stroke, memory impairment, Pharmacology, food, and the like.

FIG. 1 is a graph showing the results of measurement of HT22 cell protection effect on glutamate toxicity using 24 kinds of medicines selected according to an embodiment of the present invention.
FIG. 2 is a graph showing the results of measurement of cytotoxic effect on KA through inhibition of caspase-3 expression of hippocampal neurons using 24 kinds of medicines selected according to an embodiment of the present invention (A: Hippocampal dentin, B: whole hippocampus).
FIG. 3 is a graph showing the results of measuring the neuroprotective effect on KA by increasing CREB activity of hippocampal neurons using 24 kinds of medicines selected according to an embodiment of the present invention (A: hippocampus, B: Whole hippocampus).
FIG. 4 is a graph showing the results of measuring the proliferative effect of hippocampal neural stem cells using 24 kinds of medicines selected according to an embodiment of the present invention (A: hippocampal dentate fluid, B: whole hippocampus).
FIG. 5 is a graph showing the results of an underwater labyrinth analysis using single or multiple extracts of ginseng, omija, and rhubarb according to an embodiment of the present invention.
FIG. 6 is a graph showing the results of passive avoidance test using ginseng, omija, and rhubarb, alone or in combination, according to an embodiment of the present invention.

Hereinafter, the present invention will be described in detail.

In the present invention, the optimal components are selected for the medicines having the cognitive function improvement and the anti-aging function, and the compounding ratio of these components is derived to confirm the cell death suppression and cell protection effect on the hippocampal cell, .

The present invention provides a pharmaceutical composition for preventing or treating degenerative brain diseases, which comprises a combined extract of ginseng, omija and rhubarb as an active ingredient.

The term "extract " in the present invention means a preparation obtained by squeezing a herbal medicine with an appropriate leaching solution and concentrating by evaporating the leaching solution. The extract is obtained by extracting the diluted solution or concentrate of the extract, the dried product obtained by drying the extract, Or purified water.

The above ginseng, omija, and ginseng can be used without limitation, such as cultivated and commercially available ones. The ginseng, the omija, and the ginseng can be used as it is, and can be used as it is or can be dried. Can be used.

The combined extracts of ginseng, omija, and guinea pig may be those obtained by extracting, isolating and fractionating the natural extracts using a method of extraction, separation and fractionation known in the art.

As a suitable solvent for obtaining the combined extract of ginseng, omija, and guinea, water or an organic solvent may be used, and any pharmaceutically acceptable organic solvent may be used. Examples of the solvent include water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, and butanol, acetone, ether various solvents such as ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or as a mixture of two or more thereof. Can be used. Preferably, ethanol (alcohol) may be used as the solvent.

Examples of the extraction method include hot water extraction, cold extraction, reflux cooling, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression. The desired extract may further be subjected to a conventional fractionation process or may be purified using a conventional purification method. The method for producing the combined extract of ginseng, omija, and guinea pig of the present invention is not limited, and any known method can be used.

For example, the combined extract of ginseng, omija, and guinea-fungus, which is contained in the composition of the present invention as an active ingredient, is subjected to an additional step such as vacuum distillation, freeze drying, spray drying, or the like, And can be produced in a powder state. In addition, the primary extract can be further purified into a further purified fraction using various chromatographies such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and the like Can be obtained.

Therefore, the combined extract of ginseng, omija and guinea pigs used in the present invention is a concept including all the extracts, fractions and tablets obtained in each step of extraction, fractionation or purification, their diluted solutions, concentrates or dried products.

In the composition of the present invention, the ginseng, omija and rhizome are mixed in a weight ratio of 0.1 to 10: 0.1 to 10: 0.1 to 10, more preferably 0.5 to 5: 0.5 to 5: 0.5 to 5 , And most preferably in a weight ratio of 1: 1: 1. When the ginseng, omija, and guinea pig are mixed at the above-mentioned weight ratio, the synergistic effect due to the mixing use can be maximized as compared with the case where each component is used singly.

According to one embodiment of the present invention, the combined extract of ginseng, omija, and guinea-pigs induces expression and activity of heme oxygenase-1 (HO-1) (glutamate), kA (kainic acid) inhibits the expression of caspase-3 in hippocampal neurons induced by excitatory neurotoxicity, and increases neuronal pCREB activity to kill neuronal cells And to protect and protect nerve cells, and to prevent, ameliorate, and treat degenerative brain diseases caused by the death of nerve cells.

Wherein said degenerative brain disease is selected from the group consisting of acute chronic aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, peak disease, Creutzfeldt-Jakob disease, depression, head trauma, stroke, CNS hypoxia, cerebral ischemia, HIV, cerebrovascular disease, cerebral vascular disease, cardiovascular disease, cardiovascular disease, neurodegenerative diseases, neurodegenerative disorders, neurodegenerative disorders, neurodegenerative disorders, neurodegenerative diseases, But are not limited to, loss, radiation exposure, metabolic disease, hypothyroidism, mild cognitive impairment, memory loss due to cognitive deficit or attention deficit, cognitive, learning disability, and the like.

The complex extract is preferably contained in an amount of 0.001 to 99.9% by weight, more preferably 1 to 80% by weight, based on the total weight of the pharmaceutical composition. When the content is less than 0.001% by weight, the efficiency of taking may be poor. When the content is more than 99.9% by weight, it is difficult to formulate the composition.

The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the art. The composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, external preparations such as syrups and aerosols, and sterilized injection solutions according to a conventional method. Preferably, the compositions may be formulated into creams, gels, patches, An ointment preparation, an oral preparation, a lotion preparation, a liniment preparation, a pasta preparation or a cataplasma formulation. Suitable agents known in the art are preferably, but not limited to, those disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA).

Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When the pharmaceutical composition is formulated or formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, , Lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral use include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. The components may be added to the combined extract of the active ingredients, ginseng, omija and guinea pig, either independently or in combination.

As used herein, the term "administering" means providing a pharmaceutical composition of the present invention to a subject in any suitable manner.

The present invention relates to pharmaceutical compositions comprising an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, physician or other clinician, RTI ID = 0.0 > effective < / RTI > amount. It will be apparent to those skilled in the art that the therapeutically effective dose and frequency of administration for the pharmaceutical compositions of the present invention will vary with the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art, and can be readily determined by those skilled in the art and will vary depending upon factors such as the type of disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, Sex and diet of the patient, the time of administration, the route of administration and the rate of administration of the composition, the duration of the treatment, the drugs used concurrently, and the like. The pharmaceutical compositions of the present invention can be administered to a subject in a variety of routes. But are not limited to, intravenous, intraperitoneal, intramuscular, intraarterial, oral, intracardiac, intramedullary, intradermal, transdermal, intestinal, subcutaneous, sublingual or topical administration.

The pharmaceutical composition of the present invention may be administered in an amount of 1 to 10,000 mg / kg / day, preferably 1 to 200 mg / kg / day, and may be administered once a day or divided into several doses .

The complex extract of the present invention can be used as a health functional food, a food additive or a dietary supplement. When the complex extract is used as a food additive, it can be suitably used according to a conventional method such as adding the complex extract as it is or mixing it with another food or food ingredient.

The mixed amount of the combined extracts of ginseng, omija and rhubarb may suitably be changed according to the purpose of use (prevention, health or therapeutic treatment), and may be 0.001 to 99.9% by weight based on the total weight of the food composition By weight, more preferably 1 to 80% by weight. When the content is less than 0.001% by weight, the efficiency of ingestion may be decreased. When the content is more than 99.9% by weight, it is difficult to formulate the composition.

As a specific example, in the production of food or beverage, the complex extract of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw material. However, when it is intended for health and hygiene purposes or for the purpose of controlling health, it can be added in an amount below the above range, and there is no problem in terms of safety. Therefore, the active ingredient can be used in an amount exceeding the above range have.

There is no particular limitation on the kind of the food, but examples of food to which the compound extract of the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, Dairy products, including soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, all of which include normal health foods.

When the food composition of the present invention is prepared as a beverage, it may contain additional ingredients such as various flavors or natural carbohydrates such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweetening agents such as dextrin and cyclodextrin; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The natural carbohydrate is contained in an amount of 0.01 to 10% by weight, preferably 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.

The food composition of the present invention can be used for various foods, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusters, stabilizers, preservatives, glycerin, Carbonation agents used in beverages, etc., and may include, but is not limited to, natural fruit juices, fruit juice beverages, and flesh for the manufacture of vegetable beverages. These components may be used independently or in combination. The proportion of the above additives is not particularly limited, but is preferably within a range of 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.

For long-term consumption intended for health and hygiene purposes or health control purposes, the food composition of the present invention has no problem in terms of safety and can be taken for a long period of time.

Hereinafter, the present invention will be described in more detail with reference to examples. These embodiments are for purposes of illustration only and are not intended to limit the scope of protection of the present invention.

Example 1. Selection of medicinal herbs for improvement of senile cognitive function

We analyzed the 3,995 prescriptions described in the Dongbu - gogok for pre - investigation of medicinal products for improvement of senile cognitive function. In the analysis of these prescriptions, we extracted 11,639 terms that express the effect of prescription using text mining technique. In the life sciences (medical science), terms related to the concept of cognitive function improvement and anti-aging were analyzed, and 13 terms of cognitive function improvement and 32 terms of anti-aging function were selected. Twenty-nine prescriptions for the improvement of cognitive function and 15 prescriptions for anti-aging were selected as a result of selecting prescriptions containing 13 cognitive function improvements and 32 anti-aging functions. After re-analyzing the individual medicines for each prescription, 37 medicines were selected for cognitive function improvement and 78 medicines were selected for anti-aging. Twenty-four kinds of medicines commonly used for cognitive function improvement and anti-aging were selected except for one kind of dual inorganic compound. 70% (v / v) alcohol extracts of these medicaments were obtained. The effects of these medicines were examined in terms of the effects on hippocampal cells, which play a central role in improving cognitive function. The models were investigated in vitro and in vivo using the hippocampus of HT22 hippocampal and kainic acid (KA) mouse models saw.

division Scientific name Usage site Yield
(%) sample
number One Raw persimmon Rehmannia glutinosa Liboschitz root 13.3 AAC-01 2 Baekbokryung Poria cocos Wolf. tuckahoe 0.58 AAC-02 3 Ginseng Panax schinseng C.A.Meyer. root 7.51 AAC-03 4 McMundong Liriope platyphylla Wang et Tang tuber 33.38 AAC-04 5 Chunmun Dong Asparagus cochinchinensis Merrill tuber 25.06 AAC-05 6 Angelica Angelica gigas Nakai root 19.68 AAC-06 7 Light Dioscorea batatus Decaisne rhizome 6.44 AAC-07 8 Schisandra Schizandra chinensis Baillon fruit 27.64 AAC-08 9 Boiled Atractylodes japonica Koidzumi rhizome 8.52 AAC-09 10 Creation Atractylodes lancea D.C rhizome 7.52 AAC-10 11 Seokchangpo Acorus gramineus Soland rhizome 7.70 AAC-11 12 White porcelain Thuja orientalis Linne seed 5.67 AAC-12 13 Origin Polygala tenuifolia Willdenow root 13.79 AAC-13 14 contrast Zizyphus jujuba Miller fruit 37.43 AAC-14 15 licorice Glycyrrhiza uralensis Fisch root 14.97 AAC-15 16 health Zingiber officinale Roscoe rhizome 4.82 AAC-16 17 Ji Anemarrhena asphodeloides Bunge rhizome 13.98 AAC-17 18 dermis Citrus unshiu S. Marcov. peel 22.54 AAC-18 19 sirloin Juncus effusus Linne stalk 4.16 AAC-19 20 elecampane Saussurea costus Lipsch. root 19.29 AAC-20 21 A black protein Paeonia lactiflora Pallas root 8.28 AAC-21 22 Raw Alpinia oxyphylla Miquel seed 4.45 AAC-22 23 Celestial Cnidium officinale Makino rhizome 2.65 AAC-23 24 goldthread Coptis japonica Makino rhizome 6.24 AAC-24

Example 2. Protective effect of mouse hippocampal cell (HT22)

Various factors are involved in the improvement of cognitive function, but oxidative stress is one of the main factors. HT22 hippocampal cells treated with glutamate are typical cell models for oxidative stress, and hippocampal HT22 cells were treated with glutamate to induce glutamate toxicity in the mouse of 24 kinds of medicines selected in Example 1 for glutamate toxicity (excitotoxicity) We examined the protective effect of hippocampal cell (HT22).

Specifically, HT22 hippocampal cells were placed in 96-well plates and cultured in a CO ₂ incubator at 37 ° C for 24 hours. Twenty-four kinds of medicines selected in Example 1 were pre-treated for 24 hours at a concentration of 50 and 100 μg / ml, treated with 5 mM glutamate for 24 hours, and the cytotoxicity induced by glutamate was measured (MTT) assay for growth and proliferation. The culture solution was changed to a 0.5 mg / ml MTT solution and cultured in a dark room at 7 캜 for 4 hours. After culturing, DMSO was treated and cell viability was measured at 595 nm using a SpectraMax 190 spectrophotometer. The control group without glutamate treatment was compared with the glutamate treatment group treated with only 5 mM glutamate.

As shown in Fig. 1, it was confirmed that the treatment group treated with glutamate had a cell survival reduction of about 35% as compared with the control group treated with glutamate. In addition, ginseng, astringent ginseng, and licorice effectively reduced the toxicity of glutamate in the pretreatment group of 24 kinds of medicines.

Example 3. Protective effect on excitotoxicity of KA mouse model

Although various factors are involved in the improvement of cognitive function, excitotoxicity is one of the main factors, and the hippocampus of kainic acid (KA) mouse model, which is an ideal excitotoxic animal model, was examined immunohistochemically . Mice were anesthetized with isoflurane and perfused with 4% paraformaldehyde. After brain was extracted, the mice were fixed with the same fixative at 4 ° C for 4 hours. After immersing in 30% sucrose at 4 DEG C for 48 hours, a 20 mu m-thick frozen section was obtained. The sections were treated with blocking buffer (1X PBS / 5% normal serum / 0.3% Triton X-100) for 1 hour and caspase-3 and pCREB antibodies were then treated at 4 ° C for 12 hours. The secondary antibody was treated and embedded, and then observed with a fluorescence microscope.

3-1. Effect of KA on cell death

The expression of caspase-3, which mediates neuronal apoptosis and plays a central role in apoptosis, was examined, and the results are shown in FIG.

As shown in FIG. 2, the number of caspase-3 ⁺ / NeuN ⁺ cells in the hippocampal nucleus (A) and hippocampus (B) significantly increased in the KA treated group compared to the control group without KA treatment. However, the number of caspase-3 ⁺ / NeuN ⁺ cells in the hippocampus and whole hippocampus was significantly decreased in the pretreated group of the 24 kinds of medicines selected in Example 1, and the most effective was Omiza.

3-2. Neuroprotective effect on KA

Activation of CREB is mainly responsible for neuronal protection and CREB (pCREB) expression, which is a major factor in preventing cell death, is shown in FIG.

As shown in FIG. 3, the number of pCREB ⁺ / NeuN ⁺ cells was significantly reduced in the KA-treated experimental group compared to the control group not treated with KA by inhibiting the expression of pCREB in the hippocampal nucleus (A) and the entire hippocampus (B) . However, the number of pCREB ⁺ / NeuN ⁺ cells in the hippocampus and whole hippocampus was significantly increased in the pretreated group of the 24 kinds of medicines selected in Example 1, with rhizome having the highest effect.

3-3. Effect on hippocampal cell proliferation

The hippocampal neuron regeneration plays an important role in cognitive function. In order to examine the effect of hindbrain on neural stem cell proliferation (BrdU ⁺ cells), a synthetic thymidine analogue, bromodeoxyuridine (BrdU), was injected and labeled on the cells under proliferation. For immunohistochemical study, 20 mu m thick frozen sections were treated with BrdU antibody, embedded, and observed with a fluorescence microscope.

Experimental Results As shown in Fig. 4, the number of hippocampal neural stem cells (BrdU-positive cells) in the hippocampal nucleus (A) and the entire hippocampus (B) in the seizure-induced experimental group treated with KA Showed a slight increase. In addition, it was confirmed that the 24 kinds of medicines selected in Example 1 significantly increased the neural stem cells in the hippocampus and whole hippocampus in the pretreated group, and it was confirmed that since the medicament treatment before KA treatment, not KA effect, Were significantly proliferated. Among them, Omiza showed the highest effect.

From the above results, it could be predicted that the combination of ginseng, omija and rhubarb which showed the highest functionality for cell and animal experiments would be highly effective in improving cognitive function.

Example 4. Preparation of a combined extract of ginseng, omija, and ginseng

The ginseng, omija and guinea gins passed in the inspections were quantified as 1 wt%, 1 wt% and 1 wt%, respectively, followed by high pressure spray washing. The washed raw materials were mixed, and purified water of 3 times the weight of the raw material was administered. The mixture was extracted at a temperature of 120 ± 5 ° C for 3 hours or more and filtered through a filter paper of 8 μm. Then, the mixture was concentrated at 60 ° C with a vacuum concentrator, and then a combined extract of ginseng, omija and rhizosphere was prepared using a freeze dryer.

Example 5: Improvement of cognitive function of ginseng,

Animal behavior tests related to cognitive improvement of selected rhizomes (AAC01), ginseng (AAC03), omija (AAC08), and triple complex treatment (CAAC) were conducted. In order to analyze the memory and cognitive function improvement effects, the animal of the present invention (C57BL / 6J mouse) was treated with 500 mg / kg of Rhizophora, Ginseng, Omija, kainic acid, KA) were intraperitoneally injected. Underwater labyrinth analysis was performed between 3 and 6 days after intraperitoneal injection, and passive avoidance test was performed between 9 and 12 days.

5-1. Underwater Labyrinth Method

Underwater labyrinth analysis is a behavioral test that examines spatial memory and learning ability. When the hippocampus is normal, the experimenter easily navigates the hidden platforms with learning, while in the case of cognitive impairment, it can not find the target and wanders .

The Morris water maze method was used to test spatial perception ability. To master the Morris water maze, the platform was placed in a 100 cm diameter, 50 cm height water tank under the water at a temperature of 22 to 23 ° C, and trained for 4 days to 7 days before the KA injection. For each test, each experimental animal was placed at an arbitrary starting point to find a hidden platform. After waiting for up to 90 seconds, if the hidden platform was not found, it was considered to have failed. The experiment was conducted for 4 consecutive days. The latency, swimming speed, and swim trajectory of each platform were recorded and analyzed using SMART 2.5.18 (Panlab SLU). The results are shown in FIG. 5 .

As shown in FIG. 5, in the group treated with KA alone, the time required for finding the platform was significantly longer than that in the control group not treated with KA. However, in the experimental group treated with ginseng, ginseng, Time was shortened. In addition, when the single treatment of rhubarb, ginseng, and omija and the treatment of three kinds of compound extracts were compared, the study was repeated over time from the second day of experiment, and the significance of each was lowered, but on the first day, The combined extracts of ginseng, omija and rhubarb were found to be more effective in improving spatial perception ability.

5-2. Passive avoidance reaction test

The Passive Avoidance Test is an experiment to confirm short term learning and memory that is dependent on the hippocampus. Find out whether the complex composition of the present invention is effective in improving memory retention The passive avoidance test was performed.

The experimental equipment used was a shuttle box (NV-256-8SR) with horizontal, vertical, and height of 410 cm, 60 cm, and 255 cm. The box was divided into two rooms using a guillotine door. One room was made light and the other room was made a dark room so that the effect of lighting in the two rooms could be different. We measured the cross-over latency time from the bright room to the dark room, and the latency time is significantly reduced when the recognition is impaired. The results were analyzed using MED-PC software.

As shown in FIG. 6, the reaction time was reduced in the KA-treated group compared to the control group not treated with KA, and in the experimental group treated with the ginseng, ginseng, and Omija extract alone, It was confirmed that delayed time had an effect on short - term learning and memory. In addition, when the single treatment of ginseng, ginseng, and omija and the treatment of three kinds of compound extracts are compared, the combination extract of ginseng, omija and rhubarb according to the present invention exhibits a remarkably long lag time in the treatment of the compound extract, Learning and memory.

Formulation Example 1. Preparation of pharmaceutical preparations

Acid production

20 mg of a combined extract of ginseng, omija and rhubarb, 100 mg of lactose, and 10 mg of talt were mixed and filled in airtight bags to prepare powders.

Tablet manufacture

10 mg of a combined extract of ginseng, omija and rhubarb, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed and then tableted according to a conventional preparation method.

Capsule preparation

10 mg of a combined extract of ginseng, omija and rhizomes, 3 mg of crystalline cellulose, 14.8 mg of lactose, and 0.2 mg of magnesium stearate were mixed and filled in gelatin capsules according to a conventional capsule preparation method to prepare capsules.

Injection manufacturing

10 mg of a combined extract of ginseng, omija, and guineifin (2 ml) per ampoule, 180 mg of mannitol, 2,974 mg of sterile distilled water for injection, and 26 mg of Na ₂ HPO ₄ .2H ₂ O were prepared according to the usual injection preparation method .

Liquid preparation

20 mg of a complex extract of ginseng, omija and guinea, 10 g of isomerized sugar and 5 g of mannitol were dissolved in purified water in accordance with the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, purified water was further added thereto, adjusted to a total volume of 100 ml, filled in a brown bottle, and sterilized to prepare a liquid preparation.

Formulation Example 2. Preparation of food preparation

Health food manufacturing

100 mg of vitamin A complex acetate, 70 g of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.5 mg of vitamin B6, 0.2 g of vitamin B12, 10 mg of vitamin C, 10 g of biotin, 1.7 mg of nicotinic acid amide, 50 g of folate, 0.5 mg of calcium pantothenate, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of monobasic potassium phosphate, , 90 mg of potassium citrate, 100 mg of calcium carbonate and 24.8 mg of magnesium chloride were mixed and granules were prepared, and a health food was prepared according to a conventional method. At this time, although the composition ratio of the vitamin and mineral mixture is relatively mixed with the ingredient suitable for health food, it may be arbitrarily modified.

Health drink manufacturing

100 g of vitamin C, 100 g of vitamin E (powder), 19.75 g of iron lactate, 3.5 g of zinc oxide, 3.5 g of nicotinic acid amide, 0.2 g of vitamin A, 0.25 g of vitamin B1, 0.3 g of vitamin B2 and a predetermined amount of water were mixed and heated at 85 DEG C for about 1 hour with stirring. The resulting solution was filtered and sterilized in a sterilized 2 L container, . At this time, although the composition ratio of the ingredients suitable for the beverage is comparatively mixed, the mixture ratio may be arbitrarily varied according to the demand, the demanded country, the intended use, and the regional or national preference.

Although the present invention has been described in terms of the preferred embodiments mentioned above, it is possible to make various modifications and variations without departing from the spirit and scope of the invention. It is also to be understood that the appended claims are intended to cover such modifications and changes as fall within the scope of the invention.

Claims

A pharmaceutical composition for the prevention or treatment of degenerative brain diseases comprising an extract of ginseng, omija, and rhubarb as an active ingredient.

The method according to claim 1,
The pharmaceutical composition for preventing or treating degenerative brain diseases according to claim 1, wherein the complex extract is obtained by extracting ginseng, omija, or rhubarb with a solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof.

3. The method of claim 2,
Wherein the alcohol having 1 to 4 carbon atoms is at least one selected from the group consisting of methanol, ethanol, isopropanol, and butanol.

The method according to claim 1,
Wherein the ginseng, omija, and guinea pig are mixed in a weight ratio of 0.1 to 10: 0.1 to 10: 0.1 to 10 to prevent or treat degenerative brain diseases.

The method according to claim 1,
Wherein the complex extract is contained in an amount of 0.001 to 99.9% by weight based on the total weight of the composition.

The method according to claim 1,
Wherein the combined extract promotes caspase-3 expression and expression of pCREB. 2. A pharmaceutical composition for preventing or treating degenerative brain diseases,

The method according to claim 1,
Wherein said degenerative brain disease is selected from the group consisting of acute chronic aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, peak disease, Creutzfeldt-Jakob disease, depression, head trauma, stroke, CNS hypoxia, cerebral ischemia, HIV, cerebrovascular disease, cerebral vascular disease, cardiovascular disease, cardiovascular disease, neurodegenerative diseases, neurodegenerative disorders, neurodegenerative disorders, neurodegenerative disorders, neurodegenerative diseases, Wherein the disorder is memory, cognitive, or learning disorder due to loss, radiation exposure, metabolic disease, hypothyroidism, mild cognitive impairment, cognitive deficit or attention deficit.

A composition for preventing or improving degenerative brain diseases, which comprises a combined extract of ginseng, omija and rhubarb as an active ingredient.